Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study Meeting Abstract
| Authors: | Hamilton, E. P.; De Laurentiis, M.; Jhaveri, K. L.; Hu, X.; Ladoire, S.; Patsouris, A.; Zamagni, C.; Cui, J.; Cazzaniga, M.; Cil, T.; Jerzak, K. J.; Fuentes, C. S.; Yoshinami, T.; Rodríguez-Lescure, A.; Valota, O.; Lu, D. R.; Martignoni, M.; Parameswaran, J.; Zhi, X.; Campone, M. |
| Abstract Title: | Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-10 |
| Start Page: | LBA1000 |
| Language: | English |
| ACCESSION: | WOS:001511754500001 |
| DOI: | 10.1200/JCO.2025.43.17_suppl.LBA1000 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
